Updates on dabrafenib, trametinib, lambrolizumab, and more.
1,2
Merck’s PD-1 inhibitor, lambrolizumab, received “Breakthrough Therapy” status from the FDA based on trial data for this experimental antibodya category that may enable expedited development.3
Unfortunately, in 2011, the phase III AGENDA trial revealed disappointing data, demonstrating that Genta’s “Genasense” was not significantly superior compared with patients treated with chemotherapy alone.4
In conclusion, metastatic melanoma remains one of the most therapeutically challenging malignancies, and curative treatments remain elusive. However, for the first time in decades, new drugs have resulted in significant clinical responses. Advances in basic and clinical research have produced novel treatment strategies that target specific molecules and pathways expressed in cancer cells. One of the major focuses in melanoma therapy continues to be the understanding and targeting of signal transduction pathways responsible for the tumor’s capacity for growth and resistance to chemotherapy.5Additionally, the molecular heterogeneity of melanoma, and the recognition of numerous mechanisms of resistance to targeted therapies, support the use of a combinatorial approach to treatment. Clinical management of melanoma is therefore improving with increased understanding of the molecular pathogenesis of the tumor.6
Dosing and Regimen Changes Promote Tolerability in Advanced Melanoma
March 14th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed dosing considerations and toxicity when choosing combination treatment for patients with melanoma. This is the second of 2 articles based on this event.
Read More